Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Caris Life Sciences (CAI) Change in Accured Expenses (2024 - 2025)

Caris Life Sciences has reported Change in Accured Expenses over the past 2 years, most recently at $29.3 million for Q4 2025.

Quarterly results put Change in Accured Expenses at $29.3 million for Q4 2025, up 97.46% from a year ago — trailing twelve months through Dec 2025 was $28.5 million (changed N/A YoY), and the annual figure for FY2025 was $11.5 million, up 1329.51%.
Change in Accured Expenses for Q4 2025 was $29.3 million at Caris Life Sciences, up from $889000.0 in the prior quarter.
Over the last five years, Change in Accured Expenses for CAI hit a ceiling of $29.3 million in Q4 2025 and a floor of -$16.4 million in Q3 2024.